Status | Study |
Not yet recruiting |
Study Name: 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Peripheral T-cell Lymphoma Condition: Lymphoma, T-Cell, Peripheral Date: 2017-02-09 Interventions: Device: 18F-FDG PET/ CT 18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients |
Not yet recruiting |
Study Name: Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Peripheral T-cell Lymphoma Condition: Lymphoma, T-Cell, Peripheral Date: 2017-02-09 Interventions: Device: 18F-FDG PET/CT 18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients |
Not yet recruiting |
Study Name: Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients Condition: Peripheral T Cell Lymphoma Date: 2016-11-03 Interventions: Drug: chidamide 30mg po twice |
Recruiting |
Study Name: Chidamide for Refractory/Relapsed Peripheral T Cell Lymphoma Condition: Peripheral T Cell Lymphoma Date: 2016-10-21 Interventions: Drug: Chidamide Chidamide is given to the patients as described, and drug concentration is measured in p |
Not yet recruiting |
Study Name: Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma Condition: Peripheral T Cell Lymphoma Date: 2016-07-24 Interventions: Drug: Chidamide with ICE regimen Chidamide and ICE regimen, dosage described in arm description |
Not yet recruiting |
Study Name: Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients Condition: Peripheral T-cell Lymphoma Date: 2016-06-17 Interventions: Drug: Chidamide In the lead-in |
Completed |
Study Name: A Retrospective Study of Clinical, Phenotypic and Genetic Factors of Peripheral T-Cell Lymphomas Condition: Lymphoma, T-Cell, Peripheral Date: 2016-05-23 Interventions: Other: No Intervention |
Recruiting |
Study Name: Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell Lymphoma Condition: Peripheral T Cell Lymphoma Date: 2016-04-19 Interventions: Drug: Chidamide |
Recruiting |
Study Name: Endostar Aggressive Treatment of Peripheral T-cell Lymphoma (PTCL) Phase II Clinical Study Condition: Peripheral T-cell Lymphomas Date: 2015-07-26 Interventions: Drug: GDP GDP is a a combinati |
Recruiting |
Study Name: GDP in Frontline Chemotherapy for Patients With PTCL-NOS Condition: Lymphoma, T-Cell, Peripheral Date: 2015-03-26 Interventions: Drug: GDP chemotherapy gemcitabine (1000mg/m2 intravenously over 30 minutes on days 1 and 8), cisplatin |